GENX Stock Overview

Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with focus on nutraceuticals and pharmaceuticals in Canada. More details

GENX fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has less than 1 year of cash runway

Negative shareholders equity

Earnings have declined by 46.9% per year over past 5 years

Makes less than USD$1m in revenue (CA$4K)

+ 2 more risks

My Notes

Capture your thoughts, links and company narrative

Genix Pharmaceuticals Corporation Competitors

Psyched Wellness

CNSX:PSYC

CA$4.3m

Emergence Global Enterprises

CNSX:EMRG

CA$4.9m

Hempalta

TSXV:HEMP

CA$3.8m

Irwin Naturals

CNSX:IWIN

CA$1.0m

Price History & Performance

Summary of share price highs, lows and changes for Genix Pharmaceuticals
Historical stock prices
Current Share Price	CA$0.055
52 Week High	CA$0.09
52 Week Low	CA$0.025
Beta	-0.43
1 Month Change	10.00%
3 Month Change	57.14%
1 Year Change	175.00%
3 Year Change	-52.17%
5 Year Change	n/a
Change since IPO	-78.00%

Recent updates

Did Genix Pharmaceuticals Corporation (CVE:GENX) Insiders Buy Up More Shares?

Jan 17

Shareholder Returns

	GENX	CA Personal Products	CA Market
7D	10.0%	-1.3%	-0.5%
1Y	175.0%	-0.6%	14.9%

Return vs Industry: GENX exceeded the Canadian Personal Products industry which returned 0.3% over the past year.

Return vs Market: GENX exceeded the Canadian Market which returned 15.7% over the past year.

Price Volatility

Is GENX's price volatile compared to industry and market?
GENX volatility
GENX Average Weekly Movement	n/a
Personal Products Industry Average Movement	11.1%
Market Average Movement	8.1%
10% most volatile stocks in CA Market	17.2%
10% least volatile stocks in CA Market	2.9%

Stable Share Price: GENX's share price has been volatile over the past 3 months compared to the Canadian market.

Volatility Over Time: Insufficient data to determine GENX's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1993	n/a	Sina Pirooz	www.genixpharm.com

Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with focus on nutraceuticals and pharmaceuticals in Canada. The company develops Flu-X, an anti-viral, anti-flu, and common colds coronavirus oral and spray herbal product; Renochlor, a dietary supplement to support kidney health; and Sucanon, a herbal health supplement to manage blood sugar levels and enhance insulin sensitivity in non-insulin dependent adults. It also markets and sells nutraceuticals and pharmaceutical products, such as bee propolis capsules, calcium liquid softgels, seal oil softgels, marine lipid softgels, Lecithin softgels, fish oil softgels, EPO softgels, and spirulina powder, as well as eye ointments and drops.

Genix Pharmaceuticals Corporation Fundamentals Summary

How do Genix Pharmaceuticals's earnings and revenue compare to its market cap?
GENX fundamental statistics
Market cap	CA$2.96m
Earnings (TTM)	-CA$4.00m
Revenue (TTM)	CA$3.98k

817.8x

P/S Ratio

-0.8x

P/E Ratio

Is GENX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GENX income statement (TTM)
Revenue	CA$3.98k
Cost of Revenue	CA$1.68k
Gross Profit	CA$2.30k
Other Expenses	CA$4.00m
Earnings	-CA$4.00m

Last Reported Earnings

Jul 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.067
Gross Margin	57.77%
Net Profit Margin	-100,366.41%
Debt/Equity Ratio	-54.2%

How did GENX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/30 09:59
End of Day Share Price	2024/12/30 00:00
Earnings	2024/07/31
Annual Earnings	2023/10/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Genix Pharmaceuticals Corporation is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution